First Tracks Biotherapeutics Announces Participation In Upcoming Investor Conferences
Guggenheim 3 rd Annual Healthcare Innovation Conference, Boston
- Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Nov. 10, 2026 at 11:30am ET
Jefferies Global Healthcare Conference, London
- Format – Presentation and one-on-one investor meetings Date and Time – Monday, Nov. 16, 2026 at 4:30pm GMT / 11:30am ET
UBS Global Biopharma Conference 2026, London
- Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Nov. 17, 2026 at 11:40am GMT / 6:40am ET
Piper Sandler 38 th Annual Healthcare Conference, New York
- Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Dec. 1, 2026 at 1:30pm ET
9 th Annual Evercore Healthcare Conference, Miami
- Format – Fireside chat and one-on-one investor meetings Date and Time – Wednesday, Dec. 2, 2026 at 12:30pm ET
Live webcasts of the presentation and fireside chats will be available on the investor section of the First Tracks website at . Replays of the webcasts will be available for at least 30 days following the events.
About First Tracks Biotherapeutics
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit or follow us on LinkedIn.
Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment